Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
Strategic Plan
Whats New at the pCPA
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Qulipta (atogepant)
pCPA File Number:
22394
Negotiation Status:
Active Negotiation
Indication(s):
For the prevention of episodic migraine in adults
Sponsor/Manufacturer:
AbbVie Corporation
CADTH Project Number:
SR0724
pCPA Engagement Letter Issued:
2023-08-16
Negotiation Process Concluded:
Not Applicable